Truncated HPV 16 L1 Protein Self-Assembly in E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing HPV L1 protein in E. coli expression systems result in proteins that often lose native conformation, leading to low yields and high production costs, making large-scale industrial production of effective HPV vaccines challenging.
Innovation Solution
A truncated HPV 16 L1 protein with 4, 6, 8, 10, 20, 30, or 40 amino acids truncated at the N-terminal is expressed in an E. coli system, allowing for high-yield purification and self-assembly into virus-like particles (VLPs) that induce neutralizing antibodies, using a method that includes disrupting E. coli in a salt solution, reducing salt concentration, and redissolving with a reductant to achieve at least 50% purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If HPV L1 protein is expressed in E. coli expression systems, then production cost is reduced, but the protein often loses native conformation and yield is low
Solution Approach 1:
The invention divides the L1 protein into two functional segments: a truncated N-terminal region (amino acids 1-65 or 1-70) that facilitates proper folding and conformation, and a C-terminal region that maintains viral structure. This segmentation allows the protein to achieve both correct conformation and high yield in E. coli expression systems.
Solution Approach 2:
The invention changes the molecular weight parameter of the L1 protein by truncating the N-terminal region, creating a variant with molecular weight of 55-60 kDa instead of the wild-type 65-70 kDa. This parameter change enables the protein to maintain native conformation while being produced at high yield in E. coli.
2Manufacturing precision
If full-length HPV L1 protein is expressed in E. coli, then native conformation can be maintained, but production yield is low and purification is difficult
Solution Approach 1:
The invention extracts and removes the problematic N-terminal region (amino acids 1-65 or 1-70) from the full-length L1 protein. This extraction eliminates the portion that causes misfolding and aggregation in E. coli, thereby improving both conformation and yield while maintaining the essential C-terminal structure for viral particle assembly.
3Manufacturing precision
If eukaryotic expression systems are used, then native conformation is maintained, but production cost is high and scale-up is difficult
Solution Approach 1:
The invention creates a simplified copy of the L1 protein with truncated N-terminal region that can be produced in the simpler, lower-cost E. coli system. This truncated version (amino acids 66-200 or 67-200) maintains the essential structural and immunogenic properties of the full-length protein while enabling cost-effective large-scale production in prokaryotic systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of HPV 16 VLPs with good immunogenicity and high titer neutralizing antibodies, facilitating the development of an effective and economically viable HPV vaccine for cervical cancer prevention.
Implementation Method 1
HPV L1 protein expressed in multiple different expression systems can form Virus-like particles (VLPs) which resemble native HPV particles morphologically, without the assistance of the L2 protein. The VLP, consisting of 72 pentamers of the L1 proteins, exhibits icosahedral symmetry.
Implementation Method 2
A method includes disrupting E. coli in a salt solution, reducing salt concentration, and redissolving with a reductant to achieve at least 50% purity.
Data Source
AI summary
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.